JP2012505241A - アルツハイマー病の治療用組成物 - Google Patents

アルツハイマー病の治療用組成物 Download PDF

Info

Publication number
JP2012505241A
JP2012505241A JP2011531201A JP2011531201A JP2012505241A JP 2012505241 A JP2012505241 A JP 2012505241A JP 2011531201 A JP2011531201 A JP 2011531201A JP 2011531201 A JP2011531201 A JP 2011531201A JP 2012505241 A JP2012505241 A JP 2012505241A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
aryl
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011531201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505241A5 (enExample
Inventor
ゴシュ,アラン,ケー.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2012505241A publication Critical patent/JP2012505241A/ja
Publication of JP2012505241A5 publication Critical patent/JP2012505241A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011531201A 2008-10-10 2009-10-09 アルツハイマー病の治療用組成物 Withdrawn JP2012505241A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10443408P 2008-10-10 2008-10-10
US61/104,434 2008-10-10
US17562409P 2009-05-05 2009-05-05
US61/175,624 2009-05-05
PCT/US2009/060132 WO2010042796A1 (en) 2008-10-10 2009-10-09 Compounds for treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2012505241A true JP2012505241A (ja) 2012-03-01
JP2012505241A5 JP2012505241A5 (enExample) 2012-11-22

Family

ID=42100967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531201A Withdrawn JP2012505241A (ja) 2008-10-10 2009-10-09 アルツハイマー病の治療用組成物

Country Status (5)

Country Link
US (1) US8703947B2 (enExample)
EP (1) EP2349308A4 (enExample)
JP (1) JP2012505241A (enExample)
CA (1) CA2740107A1 (enExample)
WO (1) WO2010042796A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002938A (es) 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
EP2411000A4 (en) * 2009-03-25 2012-09-19 Comentis Inc PYRROLIDINE COMPOUNDS THAT INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USING THE SAME
US9096541B2 (en) * 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
US10085969B1 (en) * 2016-02-12 2018-10-02 University Of South Florida Sortilin binding compounds, formulations, and uses thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3847770A (en) * 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4687610A (en) * 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69316745T2 (de) * 1992-11-17 1998-07-16 Citizen Watch Co Ltd Drehgeschwindigkeitsdetektorschaltung
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5354566A (en) * 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2466284A1 (en) * 2001-11-08 2003-05-15 Elan Pharmaceuticals, Inc. N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
US7312360B2 (en) * 2001-12-06 2007-12-25 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
EP1562897B1 (en) * 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
US7291620B2 (en) * 2003-06-30 2007-11-06 Merck + Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
MXPA06001559A (es) 2003-08-08 2006-05-15 Schering Corp Inhibidores de amina ciclica bace-1 que poseen una benzamida como sustituyente.
US7585885B2 (en) * 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US7745470B2 (en) * 2005-03-10 2010-06-29 Bristol-Myers Squibb Company Isophthalates as beta-secretase inhibitors
WO2006103038A1 (en) 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
KR20080015079A (ko) * 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
WO2007058862A2 (en) * 2005-11-16 2007-05-24 Merck & Co., Inc. Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
US7902218B2 (en) * 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
CA2739875A1 (en) * 2008-10-10 2010-04-15 Comentis, Inc. Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
US8394807B2 (en) 2008-11-20 2013-03-12 Purdue Research Foundation Quinazoline inhibitors of BACE 1 and methods of using
WO2010065861A2 (en) 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease

Also Published As

Publication number Publication date
EP2349308A4 (en) 2012-09-12
EP2349308A1 (en) 2011-08-03
US20110195978A1 (en) 2011-08-11
US8703947B2 (en) 2014-04-22
CA2740107A1 (en) 2010-04-15
WO2010042796A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
JP6081354B2 (ja) 治療活性組成物およびそれらの使用方法
RU2697665C1 (ru) Производные 1,3,4-оксадиазолсульфонамида в качестве ингибиторов деацетилазы гистонов 6 и фармацевтическая композиция, содержащая их
CA2160444C (en) Aroyl-piperdine derivatives
KR102662215B1 (ko) 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
EP2925322B1 (en) Inhibitors of the renal outer medullary potassium channel
JP2023540661A (ja) CCR8阻害剤を使用してTregsを標的とする方法および組成物
JP7567041B2 (ja) ヒストン脱アセチル化酵素6阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物
WO2013138753A1 (en) Prodrugs of riluzole and their method of use
BRPI0915876B1 (pt) Composto azol, composição farmacêutica e uso do dito composto para tratamento da dor neuropática
JP2007515404A (ja) アルツハイマー病治療用のベンジルエーテルおよびベンジルアミノ系β−セクレターゼ阻害薬
JP2022188014A (ja) バニン阻害剤としてのヘテロ芳香族化合物
WO2012043891A1 (ja) 眼疾患処置薬
JP2006525990A (ja) 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
JP2012505241A (ja) アルツハイマー病の治療用組成物
JP2008535863A (ja) β−セクレターゼ活性を阻害する化合物およびその使用方法
WO2019022223A1 (ja) 環状アミン誘導体及びその医薬用途
JP7642859B2 (ja) ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物
AU2006243393A1 (en) 3 -mono- and 3 , 5-disubstituted piperidine derivatives as renin inhibitors
JP2019506442A (ja) 新規なカリウムチャネル阻害剤
WO2010065861A2 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease
JP2024519091A (ja) 炎症性疾患またはがんを処置するためのオキソインドリン化合物
RU2731618C2 (ru) Нестероидные модуляторы глюкокортиодидных рецепторов для местной доставки лекарств
WO2016006593A1 (ja) 新規ベンズオキサジン誘導体及びこれを含有する医薬
US20090281161A1 (en) Organic Compounds
AU2007260298A1 (en) Pyrrolidine compounds as renin inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121005

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131216